Cargando…

Long-term persistence with anti-osteoporosis drugs after fracture

SUMMARY: Long-term persistence with anti-osteoporosis drugs and determinants for discontinuation among fracture patients were examined. Persistence was 75.0 and 45.3 % after 1 and 5 years, respectively. Those aged ≥80 years were at increased risk of early discontinuation. Within 1 year after discont...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klop, C., Welsing, P. M. J., Elders, P. J. M., Overbeek, J. A., Souverein, P. C., Burden, A. M., van Onzenoort, H. A. W., Leufkens, H. G. M., Bijlsma, J. W. J., de Vries, F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer London 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4469296/ https://www.ncbi.nlm.nih.gov/pubmed/25822104 http://dx.doi.org/10.1007/s00198-015-3084-3

Ejemplares similares

Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000–2010
por: Klop, C., et al.
Publicado: (2015)

The Epidemiology of Hip and Major Osteoporotic Fractures in a Dutch Population of Community-Dwelling Elderly: Implications for the Dutch FRAX® Algorithm
por: Klop, Corinne, et al.
Publicado: (2015)

Predicting the 10-year risk of hip and major osteoporotic fracture in rheumatoid arthritis and in the general population: an independent validation and update of UK FRAX without bone mineral density
por: Klop, Corinne, et al.
Publicado: (2016)

Association between use of antidepressants or benzodiazepines and the risk of subsequent fracture among those aged 65+ in the Netherlands
por: van de Ven, L. I., et al.
Publicado: (2018)

Increase in prophylaxis of glucocorticoid-induced osteoporosis by pharmacist feedback: a randomised controlled trial
por: Klop, C., et al.
Publicado: (2013)

Use of β-Blockers and the Risk of Hip/Femur Fracture in the United Kingdom and The Netherlands
por: de Vries, F., et al.
Publicado: (2007)

All-cause mortality with current and past use of antidepressants or benzodiazepines after major osteoporotic and hip fracture
por: de Bruin, I. J. A., et al.
Publicado: (2019)

Bone Fracture Risk is Not Associated with the Use of Glucagon-Like Peptide-1 Receptor Agonists: A Population-Based Cohort Analysis
por: Driessen, Johanna H. M., et al.
Publicado: (2015)

Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs
por: Driessen, Johanna H. M., et al.
Publicado: (2015)

Use of anti-depressants and the risk of fracture of the hip or femur
por: van den Brand, M. W. M., et al.
Publicado: (2009)

Use of anti-depressants and the risk of fracture of the hip or femur
por: van den Brand, M. W. M., et al.
Publicado: (2009)

Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study
por: Pouwels, S., et al.
Publicado: (2010)

The epidemiology of fractures in Denmark in 2011
por: Driessen, J. H. M., et al.
Publicado: (2016)

Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied?
por: van der Goes, M. C., et al.
Publicado: (2012)

The risk of new fragility fractures in patients with chronic kidney disease and hip fracture—a population-based cohort study in the UK
por: de Bruin, I.J.A., et al.
Publicado: (2020)

Risk of infections in patients with gout: a population-based cohort study
por: Spaetgens, B., et al.
Publicado: (2017)

Calibration of FRAX ® 3.1 to the Dutch population with data on the epidemiology of hip fractures
por: Lalmohamed, A., et al.
Publicado: (2011)

Management of osteoporosis in patients hospitalized for hip fractures
por: Ip, T. P., et al.
Publicado: (2010)

Design of the SALT Osteoporosis Study: a randomised pragmatic trial, to study a primary care screening and treatment program for the prevention of fractures in women aged 65 years or older
por: Elders, P. J. M., et al.
Publicado: (2017)

Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis
por: Merlijn, T., et al.
Publicado: (2019)

Low-dose oral glucocorticoid therapy and risk of osteoporotic fractures in patients with rheumatoid arthritis: a cohort study using the Clinical Practice Research Datalink
por: Abtahi, Shahab, et al.
Publicado: (2021)

Risk of vertebral and non-vertebral fractures in patients with sarcoidosis: a population-based cohort
por: Bours, S., et al.
Publicado: (2015)

Fracture definitions in observational osteoporosis drug effects studies that leverage healthcare administrative (claims) data: a scoping review
por: Konstantelos, N., et al.
Publicado: (2022)

Implementation of osteoporosis guidelines: a survey of five large fracture liaison services in the Netherlands
por: Huntjens, K. M. B., et al.
Publicado: (2010)

Proton pump inhibitors, fracture risk and selection bias: three studies, same database, two answers
por: de Vries, F., et al.
Publicado: (2010)

Effectiveness of Remission Induction Strategies for Early Rheumatoid Arthritis: a Systematic Literature Review
por: Verhoeven, M. M. A., et al.
Publicado: (2019)

Antipsychotic use and the risk of hip/femur fracture: a population-based case–control study
por: Pouwels, S., et al.
Publicado: (2009)

Current and Future Incidence and Costs of Osteoporosis-Related Fractures in The Netherlands: Combining Claims Data with BMD Measurements
por: Lötters, Freek J. B., et al.
Publicado: (2016)

Human Evolution and Osteoporosis-Related Spinal Fractures
por: Cotter, Meghan M., et al.
Publicado: (2011)

The multi-biomarker disease activity test for assessing response to treatment strategies using methotrexate with or without prednisone in the CAMERA-II trial
por: Jurgens, M. S., et al.
Publicado: (2020)

Fracture rate in patients with myasthenia gravis: the general practice research database
por: Pouwels, S., et al.
Publicado: (2012)

GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab
por: Hadji, P., et al.
Publicado: (2016)

Dopaminergic drugs and the risk of hip or femur fracture: a population-based case–control study
por: Arbouw, M. E. L., et al.
Publicado: (2010)

Non-Publication Is Common among Phase 1, Single-Center, Not Prospectively Registered, or Early Terminated Clinical Drug Trials
por: van den Bogert, Cornelis A., et al.
Publicado: (2016)

Testing bias in clinical databases: methodological considerations
por: Velthove, Karin J, et al.
Publicado: (2010)

Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs
por: Fuggle, N. R., et al.
Publicado: (2020)

Contralateral hip fractures and other osteoporosis-related fractures in hip fracture patients: incidence and risk factors. An observational cohort study of 1,229 patients
por: Vochteloo, Anne J. H., et al.
Publicado: (2012)

A Personalized Approach to Biological Therapy Using Prediction of Clinical Response Based on MRP8/14 Serum Complex Levels in Rheumatoid Arthritis Patients
por: Nair, S. C., et al.
Publicado: (2016)

Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis
por: Höer, Ariane, et al.
Publicado: (2009)

Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis
por: Meunier, P. J., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_klh212bfj9jho00k7jsd11ui2b